Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2008-08-13 | Forward | 2:1 |
| 2006-10-24 | Forward | 2:1 |
ICON Public Limited Company is a global CRO offering comprehensive clinical development, management, and analytics services across all trial phases for pharma, biotech, medical devices, and public health clients.

ICON plc is a global CRO offering comprehensive clinical trial services across all phases, including the expanded Accellacare Site Network for specialized therapeutic areas like oncology, to efficiently support drug and device development.
| Icon | PRODUCT | Q4-2011 | Q3-2012 | Q4-2012 |
|---|---|---|---|---|
![]() | Clinical Research | $223.95M | $261.52M ▲ | $766.01M ▲ |
![]() | Central Laboratory | $18.67M | $23.98M ▲ | $63.49M ▲ |
| Map | REGION | Q4-2022 | Q1-2023 | Q2-2023 | Q4-2023 |
|---|---|---|---|---|---|
![]() | UNITED STATES | $806.76M | $844.4M ▲ | $848.02M ▲ | $1.59B ▲ |
![]() | IRELAND | $589.37M | $511.83M ▼ | $593.41M ▲ | $1.27B ▲ |
![]() | Rest Of Europe | $336.36M | $414.22M ▲ | $373.81M ▼ | $786.75M ▲ |
![]() | Rest Of World | — | $208.12M | $205.01M ▼ | — |
Overall rating: B
| PEER | PRICE | |
|---|---|---|
GH | $161.50 | COMPARE |
MEDP | $600.65 | COMPARE |
SOLV | $91.12 | COMPARE |
NBIX | $154.06 | COMPARE |
RVTY | $128.80 | COMPARE |
COO | $71.17 | COMPARE |
EHC | $120.85 | COMPARE |
UHS | $171.66 | COMPARE |